アクティブ・ターゲッテッド siRNA 配送のための腫瘍の酸性感受性ポリマーベクター
Chun-Yang Sun1, Song Shen1, Cong-Fei Xu2
1The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science & Technology of China , Hefei, Anhui 230027, PR China.
Journal of the American Chemical Society
|November 17, 2015
まとめ
新しいナノベクターは 腫瘍内の保護殻を切り離し siRNAの伝達を促進します このアプローチはPEGylationを克服する.
科学分野:
- 生物医学工学
- ナノテクノロジー
- 薬物の配達
背景:
- siRNAベクターの表面PEGylationはタンパク質吸収とRESクリアランスを阻害するが,細胞の吸収を阻害する.
- 刺激に反応し 殻から離れるナノベクターは 細胞内化を強化し 循環を延長する 解決策を提供します
- 腫瘍の細胞外pH (pHe) は有望な刺激ですが,微妙なpHの違いのために敏感なシステムを設計することは困難です.
研究 の 目的:
- 腫瘍を標的としたシRNAの全身輸送のための新しい酸感性ブリッジコポリマーを開発する.
- 刺激に反応するナノベクターを作り 細胞の吸収を向上させながら 血流を維持する
- siRNAベクトル性能に対するPEGylationの二重効果のジレンマを克服するために.
主な方法:
- 単純な酸に敏感なブリッジコポリマーの開発
- ポリエチレングリコール (PEG) コロナによるミセルプレックス配送システム (Dm-NP) の形成.
- PEG分離のためのpH反応性結合と,増強された吸収のための細胞浸透ペプチドの組み込み.
主要な成果:
- Dm-NPは,長期の循環とRES回避のために安定したPEGコロナを示した.
- 腫瘍部位での酸性結合破裂はPEG脱離を誘発し,細胞をターゲットにすることが容易になりました.
- PEGの除去時に細胞に浸透するペプチドの曝露は,細胞の吸収を著しく増加させた.
- Dm-NPは腫瘍の蓄積を効果的にし,非小細胞肺がんの増殖抑制を強めた.
結論:
- 開発されたDm-NPシステムは,長期の循環と標的細胞配送をうまくバランスをとります.
- 刺激反応性PEG分離は,腫瘍におけるナノベクターの有効性を高めるための実行可能な戦略です.
- このアプローチは,siRNAの配送とがん治療のための安全で効果的な方法を提供します.
関連する概念動画
Site-Targeted Drug Delivery Systems: Polymeric Carriers
109
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
109
Modified-Release Drug Delivery Systems: Site-Targeted
109
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
109
siRNA - Small Interfering RNAs
19.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K


